Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. clinical pregnancy and implementation success rates for ivf clinics
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Clinical Pregnancy And Implementation Success Rates For Ivf Clinics Articles & Analysis: Older

72 news found

Harmony Nominated for Industry Partner of the Year Award

Harmony Nominated for Industry Partner of the Year Award

Each year, the Southeast Service Cooperative in Minnesota presents its Outstanding Industry Partner of the Year Awards, celebrating southeast Minnesota partners who build youth skillsets and mindsets through real-world, hands-on, career-connected learning experiences that serve as a ladder to prosperity. ...

ByHarmony Enterprises, Inc.


LC-MS/MS Data Analysis Now Available Utilizing CD Genomics’ Bioinformatics-Analysis Solution

LC-MS/MS Data Analysis Now Available Utilizing CD Genomics’ Bioinformatics-Analysis Solution

Bioinformatics-Analysis is a subdivision of CD Genomics, providing reliable next-generation and third-generation high-throughput sequencing data analysis, database construction, and other related data analysis services utilizing comprehensive technology. The Product Manager at CD Genomics is pleased to announce the launch of the LC-MS/MS Data Analysis service, enabling high-performance, regulated ...

ByCD Genomics


How Great Clinical Trial Managers Stand Out From The Rest

How Great Clinical Trial Managers Stand Out From The Rest

Clinical Trial Manager roles are growing 32% faster than the national average. This job is undeniably rewarding but requires a high level of expertise and a knack for research. A clinical trial manager is responsible for many tasks, including overseeing everything from creating a valid test to its administration, recruitment, logistics, and follow-up. Hence, specific abilities ...

ByBrio Group


Biomark announces update from oongoing clinical trial using its lung cancer liquid biopsy test as it prepares for commercial launch

Biomark announces update from oongoing clinical trial using its lung cancer liquid biopsy test as it prepares for commercial launch

Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for ...

ByBioMark Diagnostics Inc.


MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

Data from the MANIFEST trial show durable improvements in both spleen volume and symptom score beyond 24 weeks with pelabresib in combination with ruxolitinib for JAK inhibitor-naïve patients An exploratory analysis of biomarkers from the MANIFEST trial indicates the potential for disease modification MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced results from analyses of the ...

ByMorphoSys AG


XF-73 Nasal Phase 3 development plans finalised

XF-73 Nasal Phase 3 development plans finalised

Targeting peak sales potential of $1 billion in the major markets Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that it has now finalised plans for its Phase 3 studies for its late-stage clinical asset, XF-73 Nasal. Highlights Discussions held ...

ByDestiny Pharma plc


VeriSIM Life Named “Predictive Analytics Solution of the Year” by BioTech Breakthrough

VeriSIM Life Named “Predictive Analytics Solution of the Year” by BioTech Breakthrough

VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced it has been selected as the winner of the “Predictive Analytics Solution of the Year" in the BioTech Breakthrough Awards program conducted by BioTech Breakthrough. Biotech Breakthrough is a leading independent ...

ByVeriSIM Life


CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society (ERS) International Conference. Data on the first 40 patients in the study demonstrated that treatment with the AeriSeal System successfully converted the ...

ByPulmonx Corporation


Empirical Spine Completes Enrollment in Pivotal IDE Clinical Trial Studying LimiFlex in Degenerative Spondylolisthesis

Empirical Spine Completes Enrollment in Pivotal IDE Clinical Trial Studying LimiFlex in Degenerative Spondylolisthesis

Empirical Spine, Inc., maker of the LimiFlex Paraspinous Tension Band, today announced completion of enrollment in its U.S. IDE trial studying the use of LimiFlex with a decompression for patients suffering from degenerative spondylolisthesis with lumbar spinal stenosis. The trial compares outcomes of patients who receive either LimiFlex or transforaminal lumbar interbody fusion (TLIF) ...

ByEmpirical Spine, Inc.


Empirical Spine Initiates PMA Submission Process for FDA Approval of Limiflex for Degenerative Spondylolisthesis

Empirical Spine Initiates PMA Submission Process for FDA Approval of Limiflex for Degenerative Spondylolisthesis

Empirical Spine, Inc., maker of the LimiFlex™ Paraspinous Tension Band, today announced initiation of the PMA process for FDA review and approval of the use of the LimiFlex with a decompression for patients suffering from degenerative spondylolisthesis with lumbar spinal stenosis. The Pivotal Trial supporting the PMA compares outcomes of patients who receive either LimiFlex or ...

ByEmpirical Spine, Inc.


Empirical Spine Completes Investigational Arm Enrollment In Pivotal IDE Clinical Trial Studying LimiFlex In Degenerative Spondylolisthesis

Empirical Spine Completes Investigational Arm Enrollment In Pivotal IDE Clinical Trial Studying LimiFlex In Degenerative Spondylolisthesis

Empirical Spine, Inc., maker of the LimiFlex Paraspinous Tension Band, today announced completion of enrollment in the investigational arm of its U.S. IDE trial studying the use of the LimiFlex with a decompression for patients suffering from degenerative spondylolisthesis with lumbar spinal stenosis. The trial compares outcomes of patients who receive either LimiFlex or transforaminal ...

ByEmpirical Spine, Inc.


enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

IRVINE, CA / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at ...

ByenVVeno Medical


Synchron Appoints Kurt Haggstrom as Chief Commercial Officer

Synchron Appoints Kurt Haggstrom as Chief Commercial Officer

Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding over 20 U.S. patents. “I am honored and excited to join the Synchron team and be part of ...

BySynchron, Inc.


SafeHeal appoints medical device industry veteran Chris Richardson as Chief Executive Officer

SafeHeal appoints medical device industry veteran Chris Richardson as Chief Executive Officer

PARIS, France/Tampa, FL – July, 11, 2022 – SafeHeal™, a leading innovator in the field of digestive surgery and developer of the Colovac device, announced today the appointment of Chris Richardson as Chief Executive Officer (CEO), who assumes responsibilities immediately. Richardson has over 30 years of experience in the medical device industry, and an extensive ...

BySafeHeal


EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus

EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus

EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in Zurich EsoCap’s technology for the topical treatment of Barrett’s esophagus was recognized by the experts for having high potential for clinical success EsoCap’s proprietary and unique targeted application technology for the upper ...

ByEsoCap AG


Kurve Therapeutics Announces Next-Gen Technology Designed for a New Approach to Treating CNS Disorders

Kurve Therapeutics Announces Next-Gen Technology Designed for a New Approach to Treating CNS Disorders

Kurve Therapeutics has succeeded in bypassing the blood-brain barrier with their patented Controlled Particle Dispersion® (CPD) technology, creating new hope in the treatment of central nervous system disorders. The company urges CNS researchers to reach out for collaboration in providing care for this very large global population. Led by a team of experienced entrepreneurs with ...

ByKurve Therapeutics, Inc.


Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty

Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty

100% clinical success rate: zero complications linked to robot up to 30 days post-procedure >95% technical success rate 84.5% average reduction in physician radiation exposure Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today presents the results of its R-Evolution clinical study at the international ...

ByRobocath


ImmunogenX Highlighted at Pre-Eminent Celiac Disease Conference

ImmunogenX Highlighted at Pre-Eminent Celiac Disease Conference

On the basis of clinical success and acknowledged leadership in the field of celiac disease, the organizers of the International Celiac Disease Symposium (ICDS) have invited Jack Syage PhD, CEO of ImmunogenX, to deliver a panel talk and join the Conference Faculty. ICDS is held internationally every other year and is considered the premier conference for celiac disease. This year it will be held ...

ByEntero Therapeutics, Inc.


Cerapedics Announces Results from Clinical Trial of i-FACTOR Peptide Enhanced Bone Graft in Lumbar Fusion Surgery

Cerapedics Announces Results from Clinical Trial of i-FACTOR Peptide Enhanced Bone Graft in Lumbar Fusion Surgery

Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide Enhanced Bone Graft in non-instrumented lumbar fusion surgery has been published in the May 2020, Volume 20, Issue 5 print of The Spine Journal as the lead article. The data demonstrate that elderly patients in Denmark treated with i-FACTOR bone graft plus local bone had a ...

ByCerapedics, Inc.


VeriSIM Life Announces Acquisition of Molomics Biotech

VeriSIM Life Announces Acquisition of Molomics Biotech

VeriSIM Life (VeriSIM), the leading Artificial Intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced the acquisition of Molomics Biotech, a privately-held drug discovery company that leverages proprietary AI technology to design more efficacious and safer therapeutics to achieve higher successes in clinical trials. Founded in 2015 in ...

ByVeriSIM Life

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT